H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

Clinical trial NCT02960230 · COMPLETED

Trial details

NCT number: NCT02960230
Sponsor: Sabine Mueller, MD, PhD
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Intrinsic Pontine Glioma Glioma Diffuse Midline Glioma, H3 K27M-Mutant

Start date: 2016-11-18
Primary completion: 2023-12-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.